Evidence map›Paper›PMID 28787528›Full record

ArticleJournal of surgical oncology2018

Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.

Koji Matsuo, Kwong-Kwok Wong, Christina Fotopoulou, Erin A Blake, Sharon E Robertson, Tanja Pejovic, Marina Frimer, Vishakha Pardeshi, Wei Hu, Jong-Sun Choi and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Koji MatsuoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California.ORCID http://orcid.org/0000-0002-6232-8701
Kwong-Kwok WongOvarian Cancer Action Research Center, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Christina FotopoulouDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colarodo.
Erin A BlakeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, Tampa, Florida.
Sharon E RobertsonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, New York, New York.
Tanja PejovicDepartment of Pathology, Wayne State University, Detroit, Michigan.
Marina FrimerDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Vishakha PardeshiDepartment of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, New York, New York.
Wei HuOvarian Cancer Action Research Center, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Jong-Sun ChoiOvarian Cancer Action Research Center, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Charlotte C SunOvarian Cancer Action Research Center, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Abby M RichmondDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon.
Jenna Z MarcusDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Maren A M HilliardDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California.
Sayedamin MostofizadehDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California.
Paulette Mhawech-FaucegliaDepartment of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eman AbdulfatahDepartment of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, New York, New York.
Miriam D PostDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon.
Ozlen SaglamDepartment of Pathology, University of Southern California, Los Angeles, California.
Mian M K ShahzadDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, New York, New York.
Rouzan G KarabakhtsianDepartment of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, New York, New York.
Rouba Ali-FehmiClinical Discovery Unit, Early Clinical Development, AstraZeneca, Cambridge, UK.
Hani GabraDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colarodo.
Lynda D RomanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California.
Anil K SoodOvarian Cancer Action Research Center, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
David M GershensonOvarian Cancer Action Research Center, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

BACKGROUND AND

objectivesTo examine association of lympho-vascular space invasion (LVSI) with clinico-pathological factors and to evaluate survival of women with low-grade serous ovarian carcinoma containing areas of LVSI.

methodsThis is a multicenter retrospective study examining consecutive cases of surgically treated stage I-IV low-grade serous ovarian carcinoma (n = 178). Archived histopathology slides for the ovarian tumors were reviewed, and LVSI was scored as present or absent. LVSI status was correlated to clinico-pathological findings and survival outcome.

resultsLVSI was seen in 79 cases (44.4%, 95% confidence interval [CI] 37.1-51.7). LVSI was associated with increased risk of omental metastasis (87.0% vs 64.9%, odds ratio [OR] 3.62, P = 0.001), high pelvic lymph node ratio (median 12.9% vs 0%, P = 0.012), and malignant ascites (49.3% vs 32.6%, OR 2.01, P = 0.035). On multivariable analysis, controlling for age, stage, and cytoreductive status, presence of LVSI in the ovarian tumor remained an independent predictor for decreased progression-free survival (5-year rates 21.0% vs 35.7%, adjusted-hazard ratio 1.57, 95%CI 1.06-2.34, P = 0.026). LVSI was significantly associated with increased risk of recurrence in lymph nodes (OR 2.62, 95%CI 1.08-6.35, P = 0.047).

conclusionLVSI in the ovarian tumor is associated with adverse clinico-pathological characteristics and decreased progression-free survival in women with low-grade serous ovarian carcinoma.

Indexed as

AdultCystadenocarcinoma, SerousCytoreduction Surgical ProceduresFemaleFollow-Up StudiesHumansLymphatic VesselsLymph Node ExcisionLymph NodesMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisRetrospective StudiesSurvival Ratelow-grade serouslymphovascular space invasionovarian cancer

Identifiers

PMID28787528
PMCPMC7526036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.